ASC30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
Ascletis Pharma (China) Co · Phase 1 · Completed · Enrollment 72
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| SAD Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| SAD Cohort 5 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| MAD Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |